{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T15:40:01Z","timestamp":1782402001588,"version":"3.54.5"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Hisamitsu Pharmaceutical Co., Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pain Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40122-024-00687-2","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T15:12:20Z","timestamp":1734448340000},"page":"329-338","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparative Evaluation of Cyclooxygenase\u00a0Inhibition Profiles Across Various NSAID Forms and Doses: Implications for Efficacy and Adverse Effects"],"prefix":"10.1007","volume":"14","author":[{"given":"Kenshu","family":"Shirakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Takeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Kuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Terahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"687_CR1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.clinthera.2010.04.009","volume":"32","author":"JM Scheiman","year":"2010","unstructured":"Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther. 2010;32:667\u201377.","journal-title":"Clin Ther"},{"key":"687_CR2","first-page":"655","volume":"10","author":"Z Afshin","year":"2011","unstructured":"Afshin Z, Sara A. Selective COX-2 inhibitors: a review of their structure-activity relationships. Iran J Pharm Res. 2011;10:655\u201383.","journal-title":"Iran J Pharm Res"},{"key":"687_CR3","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/sj.bjp.0702897","volume":"128","author":"JA Mitchell","year":"1999","unstructured":"Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Br J Pharmacol. 1999;128:1121\u201332.","journal-title":"Br J Pharmacol"},{"key":"687_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117631","volume":"251","author":"M Arora","year":"2020","unstructured":"Arora M, Choudhary S, Singh PK, Sapra B, Silakari O. Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: a review. Life Sci. 2020;251:117631.","journal-title":"Life Sci"},{"key":"687_CR5","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/ddr.22118","volume":"84","author":"SY Ewieda","year":"2023","unstructured":"Ewieda SY, Ahmed EM, Hassan RA, Hassan MSA. Pyridazine derivatives as selective COX-2 inhibitors: a review on recent updates. Drug Dev Res. 2023;84:1595\u2013623.","journal-title":"Drug Dev Res"},{"key":"687_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0014-2999(98)00078-8","volume":"347","author":"S Kawai","year":"1998","unstructured":"Kawai S, Nishida S, Kato M, et al. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol. 1998;347:87\u201394.","journal-title":"Eur J Pharmacol"},{"key":"687_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0002-9343(98)00091-6","volume":"104","author":"B Cryer","year":"1998","unstructured":"Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med. 1998;104:413\u201321.","journal-title":"Am J Med"},{"key":"687_CR8","unstructured":"ZICTHORU\u00ae Tapes 75\u00a0mg [Package insert] (translated from Japanese). Hisamitsu Pharmaceutical Co., Inc."},{"key":"687_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/mds3.10069","volume":"3","author":"D Bird","year":"2020","unstructured":"Bird D, Ravindra NM. Transdermal drug delivery and patches\u2014an overview. Med Devices Sens. 2020;3:e10069.","journal-title":"Med Devices Sens"},{"key":"687_CR10","first-page":"741","volume":"78","author":"U Eiji","year":"2021","unstructured":"Eiji U, Takaaki T, Koji O, Eriko T. Pharmacokinetics of diclofenac sodium patch (HP-3150) for relieving cancer pain. (translated from Japanese). Jpn J Med Pharm Sci. 2021;78:741\u201358.","journal-title":"Jpn J Med Pharm Sci"},{"key":"687_CR11","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/(SICI)1099-081X(199804)19:3<169::AID-BDD83>3.0.CO;2-C","volume":"19","author":"NM Idkaidek","year":"1998","unstructured":"Idkaidek NM, Amidon GL, Smith DE, Najib NM, Hassan MM. Determination of the population pharmacokinetic parameters of sustained-release and enteric-coated oral formulations, and the suppository formulation of diclofenac sodium by simultaneous data fitting using NONMEM. Biopharm Drug Dispos. 1998;19:169\u201374.","journal-title":"Biopharm Drug Dispos"},{"key":"687_CR12","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1097\/j.pain.0000000000002494","volume":"163","author":"S Yamaguchi","year":"2022","unstructured":"Yamaguchi S, Terahara T, Okawa K, Inakura H. A multicenter, randomized, double-blind, placebo-controlled, comparative study to evaluate the efficacy and safety of newly developed diclofenac patches in patients with cancer pain. Pain. 2022;163:1303\u201312.","journal-title":"Pain"},{"key":"687_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s40122-023-00478-1","volume":"23","author":"T Taguchi","year":"2023","unstructured":"Taguchi T, Yamaguchi S, Terahara T, Okawa K, Inakura H. Systemically acting diclofenac sodium patch for control of low back pain: a randomized, double-blind, placebo-controlled study in Japan. Pain Ther. 2023;23:529\u201342.","journal-title":"Pain Ther"},{"key":"687_CR14","first-page":"1705","volume":"271","author":"P Patrignani","year":"1994","unstructured":"Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 1994;271:1705\u201312.","journal-title":"J Pharmacol Exp Ther"},{"key":"687_CR15","unstructured":"Voltaren\u00ae Tablets 25\u00a0mg [Pharmaceutical interview form] (translated from Japanese). Novartis Pharma K.K."},{"key":"687_CR16","unstructured":"Voltaren\u00ae SUPPO 12.5\/25\/50\u00a0mg [Pharmaceutical interview form] (translated from Japanese). Novartis Pharma K.K."},{"key":"687_CR17","unstructured":"ZICTHORU\u00ae Tapes 75\u00a0mg [Pharmaceutical interview form] (translated from Japanese). Hisamitsu Pharmaceutical Co., Inc."},{"key":"687_CR18","unstructured":"Celecox\u00ae Tablets 100\/200\u00a0mg [Pharmaceutical interview form] (translated from Japanese). Viatris Inc."},{"key":"687_CR19","unstructured":"OSTELUC\u00ae TABLETS 100\/200 [Pharmaceutical interview form] (translated from Japanese). ASKA Pharmaceutical Co., Ltd."},{"key":"687_CR20","unstructured":"FROBEN\u00ae Tablets 40 [Pharmaceutical interview form] (translated from Japanese). KAKEN PHARMACEUTICAL CO., LTD."},{"key":"687_CR21","unstructured":"BRUFEN\u00ae Tablets 100\/200 [Pharmaceutical interview form] (translated from Japanese). KAKEN PHARMACEUTICAL CO., LTD."},{"key":"687_CR22","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1093\/rheumatology\/keh627","volume":"44","author":"DR Huntjens","year":"2005","unstructured":"Huntjens DR, Danhof M, Della Pasqua OE. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology. 2005;44:846\u201359.","journal-title":"Rheumatology"},{"key":"687_CR23","first-page":"341","volume":"51","author":"H Fukase","year":"2023","unstructured":"Fukase H, Seiji F, Yamamoto T, et al. An endoscopic study of the influence of a systemic patch containing diclofenac sodium on the upper gastrointestinal mucosa in healthy middle-aged and elderly men and women. (translated from Japanese). Jpn Pharmacol Ther. 2023;51:341\u201350.","journal-title":"Jpn Pharmacol Ther"}],"container-title":["Pain and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-024-00687-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40122-024-00687-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40122-024-00687-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T16:44:58Z","timestamp":1737477898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40122-024-00687-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["687"],"URL":"https:\/\/doi.org\/10.1007\/s40122-024-00687-2","relation":{},"ISSN":["2193-8237","2193-651X"],"issn-type":[{"value":"2193-8237","type":"print"},{"value":"2193-651X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]},"assertion":[{"value":"9 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Shigeki Yamaguchi has received honoraria from Hisamitsu Pharmaceutical Co., Inc., and The Nakatomi Foundation. Shigeki Yamaguchi is an Editorial Board member of Pain and Therapy. Shigeki Yamaguchi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Kenshu Shirakawa has received honoraria from Hisamitsu Pharmaceutical Co., Inc. Takaaki Terahara, Hidekazu Kuma, and Masafumi Takeno are employees of Hisamitsu Pharmaceutical Co., Inc., Tokyo, Japan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in compliance with the Declaration of Helsinki of 1964. Protocol approval for the conduct of this study was obtained from the Medical Corporation Heishinkai OPHAC Hospital Institutional Review Board. All volunteers provided written informed consent for the use of their blood in the study. Throughout the study period, no ethical problems or medical malpractice occurred and the identities of the volunteers were kept confidential.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}